Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies

Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia

(2018) Ilona Baraniak et al.   JOURNAL OF INFECTIOUS DISEASES

The pentameric complex drives immunologically covert cell–cell transmission of wild-type human cytomegalovirus

(2017) Isa Murrell et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus

(2017) Anna Bootz et al.   PLoS Pathogens

Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial

(2016) David I. Bernstein et al.   VACCINE

Preclinical evaluations of peptide-conjugate vaccines targeting the antigenic domain-2 of glycoprotein B of human cytomegalovirus

(2016) Adam C. Finnefrock et al.   Human Vaccines & Immunotherapeutics

Immune correlates of vaccine protection against HIV-1 acquisition

(2015) Lawrence Corey et al.   Science Translational Medicine

The pathogenesis of human cytomegalovirus

(2014) Paul Griffiths et al.   JOURNAL OF PATHOLOGY

Identification of a Neutralizing Epitope within Antigenic Domain 5 of Glycoprotein B of Human Cytomegalovirus

(2014) Anna-Katharina Wiegers et al.   JOURNAL OF VIROLOGY

Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies

(2014) Anna Kabanova et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mechanism for neutralizing activity by the anti-CMV gH/gL monoclonal antibody MSL-109

(2014) A. E. Fouts et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural Basis for the Recognition of Human Cytomegalovirus Glycoprotein B by a Neutralizing Human Antibody

(2014) Nadja Spindler et al.   PLoS Pathogens

Adaptive reconfiguration of the human NK-cell compartment in response to cytomegalovirus: A different perspective of the host-pathogen interaction

(2013) Aura Muntasell et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Cross-Reactive Influenza-Specific Antibody-Dependent Cellular Cytotoxicity Antibodies in the Absence of Neutralizing Antibodies

(2013) S. Jegaskanda et al.   JOURNAL OF IMMUNOLOGY

Neutralizing antibodies are unable to inhibit direct viral cell-to-cell spread of human cytomegalovirus

(2013) Christian L. Jacob et al.   VIROLOGY

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

(2012) Barton F. Haynes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human Cytomegalovirus Escapes a Naturally Occurring Neutralizing Antibody by Incorporating It into Assembling Virions

(2011) Kate Manley et al.   Cell Host & Microbe

Neutralizing Anti-gH Antibody of Varicella-Zoster Virus Modulates Distribution of gH and Induces Gene Regulation, Mimicking Latency

(2011) K. Shiraki et al.   JOURNAL OF VIROLOGY

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

(2011) Paul D Griffiths et al.   LANCET

Human cytomegalovirus activation of ERK and myeloid cell leukemia-1 protein correlates with survival of latently infected cells

(2011) M. B. Reeves et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

B Cell Repertoire Analysis Identifies New Antigenic Domains on Glycoprotein B of Human Cytomegalovirus which Are Target of Neutralizing Antibodies

(2011) Sonja Pötzsch et al.   PLoS Pathogens

Human cytomegalovirus immunity and immune evasion

(2010) Sarah E. Jackson et al.   VIRUS RESEARCH

Human Cytomegalovirus Glycoprotein B Is Required for Virus Entry and Cell-to-Cell Spread but Not for Virion Attachment, Assembly, or Egress

(2009) M. K. Isaacson et al.   JOURNAL OF VIROLOGY

Vaccine Prevention of Maternal Cytomegalovirus Infection

(2009) Robert F. Pass et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers

(2009) David I. Bernstein et al.   VACCINE

Improving Outcomes for Solid-Organ Transplant Recipients At Risk from Cytomegalovirus Infection: Late-Onset Disease and Indirect Consequences

(2008) C. Legendre et al.   CLINICAL INFECTIOUS DISEASES

Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection

(2008) Xiaohong Cui et al.   VACCINE